Therefore, unique targeting agents which can recognise and bind exclusively to cancer-associated antigens, such as tumour antigen presenting HLAs, are necessary to improve on conventional targeting strategies which usually depend on the expression cell surface proteins commonly shared between normal and cancerous cell types. Here, HLA-S is linked to cancer.